Medical supply and logistics company Owens & Minor (NYSE: OMI) will be announcing earnings results this Monday before market hours. Here’s what you need to know.
Owens & Minor missed analysts’ revenue expectations by 1.6% last quarter, reporting revenues of $2.63 billion, flat year on year. It was a slower quarter for the company, with a slight miss of analysts’ full-year EPS guidance estimates.
Is Owens & Minor a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Owens & Minor’s revenue to grow 2.1% year on year to $2.73 billion, slowing from the 4.2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.28 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Owens & Minor has missed Wall Street’s revenue estimates three times over the last two years.
Looking at Owens & Minor’s peers in the healthcare providers & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. McKesson delivered year-on-year revenue growth of 23.4%, beating analysts’ expectations by 1.4%, and CVS Health reported revenues up 8.4%, topping estimates by 5.1%. McKesson traded down 1.1% following the results while CVS Health’s stock price was unchanged.
Read our full analysis of McKesson’s results here and CVS Health’s results here.
Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 5.1% on average over the last month. Owens & Minor is down 20.8% during the same time and is heading into earnings with an average analyst price target of $9.50 (compared to the current share price of $6.43).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
